Last reviewed · How we verify
Use of buprenorphine with FAO > 30 OME
Use of buprenorphine with FAO > 30 OME is a Partial mu-opioid receptor agonist Small molecule drug developed by Fox Chase Cancer Center. It is currently FDA-approved for Moderate to severe pain, Opioid use disorder (maintenance treatment).
Buprenorphine is a partial mu-opioid receptor agonist that provides analgesia and is used in opioid-dependent patients, with dose adjustment required when combined with other opioids exceeding 30 oral morphine equivalents.
Buprenorphine is a partial mu-opioid receptor agonist that provides analgesia and is used in opioid-dependent patients, with dose adjustment required when combined with other opioids exceeding 30 oral morphine equivalents. Used for Moderate to severe pain, Opioid use disorder (maintenance treatment).
At a glance
| Generic name | Use of buprenorphine with FAO > 30 OME |
|---|---|
| Sponsor | Fox Chase Cancer Center |
| Drug class | Partial mu-opioid receptor agonist |
| Target | Mu-opioid receptor (μ-OR) |
| Modality | Small molecule |
| Therapeutic area | Pain Management / Opioid Use Disorder |
| Phase | FDA-approved |
Mechanism of action
Buprenorphine binds with high affinity to mu-opioid receptors in the central nervous system, producing analgesia through partial agonism. When used in patients already taking opioids at doses greater than 30 OME (oral morphine equivalents), careful dose titration and monitoring are required due to the risk of overdose, respiratory depression, and potential opioid withdrawal. This represents a clinical dosing guideline rather than a distinct mechanism.
Approved indications
- Moderate to severe pain
- Opioid use disorder (maintenance treatment)
Common side effects
- Respiratory depression
- Sedation
- Constipation
- Nausea
- Headache
- Dizziness
Key clinical trials
- Buprenorphine for Cancer Pain (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Use of buprenorphine with FAO > 30 OME CI brief — competitive landscape report
- Use of buprenorphine with FAO > 30 OME updates RSS · CI watch RSS
- Fox Chase Cancer Center portfolio CI
Frequently asked questions about Use of buprenorphine with FAO > 30 OME
What is Use of buprenorphine with FAO > 30 OME?
How does Use of buprenorphine with FAO > 30 OME work?
What is Use of buprenorphine with FAO > 30 OME used for?
Who makes Use of buprenorphine with FAO > 30 OME?
What drug class is Use of buprenorphine with FAO > 30 OME in?
What development phase is Use of buprenorphine with FAO > 30 OME in?
What are the side effects of Use of buprenorphine with FAO > 30 OME?
What does Use of buprenorphine with FAO > 30 OME target?
Related
- Drug class: All Partial mu-opioid receptor agonist drugs
- Target: All drugs targeting Mu-opioid receptor (μ-OR)
- Manufacturer: Fox Chase Cancer Center — full pipeline
- Therapeutic area: All drugs in Pain Management / Opioid Use Disorder
- Indication: Drugs for Moderate to severe pain
- Indication: Drugs for Opioid use disorder (maintenance treatment)
- Compare: Use of buprenorphine with FAO > 30 OME vs similar drugs
- Pricing: Use of buprenorphine with FAO > 30 OME cost, discount & access